Optimi Health (TSE:OPTI)
:OPTI
Top Page
Optimi Health
(OPTI)
Select Model
Select Model
Rating:44Neutral
Price Target:
C$0.30
▼(-5.94% Downside)
Action:ReiteratedDate:03/18/26
The score is held down primarily by weak financial performance—sharp revenue decline, negative gross profit, ongoing losses, negative free cash flow, and higher leverage. Technical indicators are largely neutral and do not materially offset the fundamental risk, while valuation is constrained by a negative P/E and no dividend yield data.
Positive Factors
Structural market exposure
Optimi operates in the emerging psychedelics and functional mushroom wellness markets, which are multi-year structural growth areas tied to mental-health and wellness trends. Regulatory progress and medical interest provide a durable addressable market for licensed producers over the next several years.
Negative Factors
Severe top-line weakness
Revenue has contracted materially and the absolute sales base is tiny, limiting economies of scale and making it hard to cover fixed costs. Persistent weak top-line trends undermine prospects for margin recovery and make the business dependent on new commercial traction or external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Structural market exposure
Optimi operates in the emerging psychedelics and functional mushroom wellness markets, which are multi-year structural growth areas tied to mental-health and wellness trends. Regulatory progress and medical interest provide a durable addressable market for licensed producers over the next several years.
Read all positive factors
Optimi Health (OPTI) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$28.55M
Dividend YieldN/A
Average Volume (3M)169.72K
Price to Earnings (P/E)―
Beta (1Y)0.37
Revenue Growth65.16%
EPS Growth33.18%
CountryCA
Employees9
SectorHealthcare
Sector Strength45
IndustryAgricultural Farm Products
Share Statistics
EPS (TTM)N/A
Shares Outstanding96,776,920
10 Day Avg. Volume137,724
30 Day Avg. Volume169,715
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)5.70
Price to Sales (P/S)87.81
P/FCF Ratio-13.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Optimi Health Business Overview & Revenue Model
Company Description
Optimi Health Corp. develops an integrated functional mushroom brand that focuses on the health and wellness food markets in Canada. The company also focuses on the cultivation, extraction, processing, and distribution of strains of functional mus...
How the Company Makes Money
null...
Optimi Health Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
28
Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 426.30K | 389.85K | 181.09K | 80.72K | 0.00 |
| Gross Profit | -2.07M | 270.91K | -157.04K | 53.92K | -47.12K |
| EBITDA | -2.23M | -4.74M | -4.42M | -7.03M | -5.95M |
| Net Income | -3.71M | -6.04M | -5.19M | -7.38M | -6.04M |
Balance Sheet | |||||
| Total Assets | 15.21M | 14.55M | 16.49M | 16.82M | 23.46M |
| Cash, Cash Equivalents and Short-Term Investments | 1.15M | 103.66K | 1.34M | 1.89M | 12.43M |
| Total Debt | 6.68M | 2.75M | 1.71M | 157.58K | 250.84K |
| Total Liabilities | 8.64M | 4.98M | 3.28M | 797.66K | 2.40M |
| Stockholders Equity | 6.57M | 9.58M | 13.21M | 16.02M | 21.07M |
Cash Flow | |||||
| Free Cash Flow | -2.72M | -4.43M | -4.41M | -11.73M | -10.96M |
| Operating Cash Flow | -2.63M | -4.28M | -3.60M | -4.58M | -6.02M |
| Investing Cash Flow | -88.38K | -154.02K | -706.02K | -3.15M | -9.19M |
| Financing Cash Flow | 3.76M | 3.19M | 3.76M | 1.19M | 19.18M |
Optimi Health Technical Analysis
Positive
0.32
Price Trends
0.31
Negative
0.32
Negative
0.28
Positive
Market Momentum
>-0.01
Negative
51.78
Neutral
55.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:OPTI, the sentiment is Positive. The current price of 0.32 is above the 20-day moving average (MA) of 0.29, above the 50-day MA of 0.31, and above the 200-day MA of 0.28, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 51.78 is Neutral, neither overbought nor oversold. The STOCH value of 55.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:OPTI.
Optimi Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | C$32.92M | 29.79 | 7.78% | ― | 28.55% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | C$27.35M | -3.31 | -19.10% | ― | 18.06% | 34.58% | |
46 Neutral | C$18.85M | -5.08 | -68.32% | ― | 2.41% | 74.61% | |
45 Neutral | C$6.92M | 5.19 | ― | ― | 15.64% | 58.47% | |
44 Neutral | C$28.55M | -4.90 | -57.28% | ― | 65.16% | 33.18% | |
42 Neutral | C$15.83M | -4.62 | 75.85% | ― | 95.76% | 22.56% |
* Healthcare Sector Average
TSE:OPTI
Optimi Health
0.30
0.10
51.28%
TSE:DOSE
Rapid Dose Therapeutics Corp
0.12
-0.07
-36.84%
TSE:LABS
MediPharm Labs
0.07
-0.02
-23.53%
TSE:PCLO
PharmaCielo
0.05
-0.04
-43.75%
TSE:ROMJ
Rubicon Organics
0.49
-0.02
-3.92%
TSE:AVCN
Avicanna
0.15
-0.09
-37.50%
Optimi Health Corporate Events
Delistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and ComplianceStock Split
Optimi Health Moves to List on Nasdaq With U.S. Share Offering and 30-for-1 Consolidation
Positive
Mar 16, 2026
Optimi Health plans to pursue a listing on the Nasdaq Capital Market under the ticker “OPTH” alongside an underwritten public offering of common shares in the United States. The company has filed a registration statement with the U.S. ...
Business Operations and StrategyProduct-Related Announcements
Optimi Health Advances Psilocybin Rollout for Treatment-Resistant Depression in Australia
Positive
Feb 26, 2026
Optimi Health has begun early clinical rollout of its naturally derived 5 mg psilocybin capsules for patients with treatment-resistant depression in Australia, marking the first patients of 2026 treated outside sponsor-led clinical trials under th...
Business Operations and StrategyProduct-Related Announcements
Optimi Health Expands Australian Footprint With Psilocybin Export for TRD
Positive
Feb 19, 2026
Optimi Health has completed the export of its GMP-manufactured natural 5 mg psilocybin capsules to Australia for use in patients with treatment-resistant depression under the country’s Authorised Prescriber Scheme. This marks the companyR...
Business Operations and StrategyProduct-Related Announcements
Optimi Health Expands MDMA-Assisted PTSD Treatments Across Australian Clinics
Positive
Feb 17, 2026
Optimi Health has begun the first MDMA-assisted treatments of 2026 at an expanded network of authorized clinics in Australia, under the country’s Authorised Prescriber Scheme. The company is supplying its 40 mg and 60 mg MDMA capsules direct...
Business Operations and Strategy
Optimi Health Ships MDMA to Australia for PTSD Treatment Programs
Positive
Feb 9, 2026
Optimi Health has completed its first MDMA export of 2026 to Australia, shipping 1,000 standardized 60 mg capsules for use in authorized clinical programs treating Post-Traumatic Stress Disorder under the country’s Authorised Prescriber Sche...
Business Operations and StrategyProduct-Related Announcements
Optimi Health Begins 2026 Shipments of MDMA and Psilocybin Capsules to Australia
Positive
Jan 26, 2026
Optimi Health has completed its first 2026 production cycle of MDMA and psilocybin capsules for the Australian market, with 1,000 MDMA capsules (60 mg) and 1,000 naturally derived psilocybin capsules (5 mg) now fully packaged, labeled and batch-re...
Business Operations and StrategyExecutive/Board Changes
Optimi Health Grants Equity Incentives and Launches New Investor Awareness Campaigns
Positive
Jan 16, 2026
Optimi Health has approved an equity incentive grant comprising 850,000 stock options and 555,000 restricted share rights to directors, officers, employees, and key individuals, with the aim of aligning compensation with long-term growth and reten...
Business Operations and Strategy
Optimi Health to Court Institutional Investors at Sidoti Micro-Cap Conference
Positive
Jan 14, 2026
Optimi Health Corp. will present at the Sidoti Micro-Cap Virtual Conference on January 21-22, 2026, where CEO Dane Stevens is scheduled to host a virtual presentation and one-on-one meetings with institutional investors. By engaging directly with ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.